While the effect of VASCEPA on the risk of pancreatitis in patients with sHTG has not been determined, data from the Company’s pivotal MARINE study in patients with TGs between 500 and 2,000 mg/dL, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback